Merck & Co., Inc. (MRK) News Today $98.05 -1.47 (-1.48%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and MoreDecember 22 at 2:51 PM | benzinga.comIs Merck the Next Big Weight-Loss Stock?December 22 at 6:45 AM | fool.comMerck & Co., Inc. (NYSE:MRK) Cut to Market Perform at BMO Capital MarketsDecember 22 at 3:27 AM | americanbankingnews.comStrategic Moves in Cardiometabolic Space: Merck’s Buy Rating for Innovative Combination TherapiesDecember 20 at 7:28 PM | markets.businessinsider.comMerck downgraded to Market Perform from Outperform at BMO CapitalDecember 20 at 2:28 PM | markets.businessinsider.comMerck & Co., Inc. (NYSE:MRK) Stock Price Down 0.8% - Time to Sell?Merck & Co., Inc. (NYSE:MRK) Trading Down 0.8% - Should You Sell?December 20 at 2:13 PM | marketbeat.comInvesting in Merck (NYSE:MRK) three years ago would have delivered you a 43% gainDecember 20 at 9:27 AM | finance.yahoo.comIs Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?December 20 at 9:27 AM | msn.comBMO Capital Markets Downgrades Merck & Co., Inc. (NYSE:MRK) to Market PerformBMO Capital Markets lowered shares of Merck & Co., Inc. from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $136.00 to $105.00 in a report on Friday.December 20 at 8:47 AM | marketbeat.comWant to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income StocksDecember 20 at 7:45 AM | fool.comMerck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific AntibodyDecember 20 at 6:45 AM | businesswire.comMerck’s doravirine/islatravir combination meets efficacy endpoint in HIV-1December 19 at 3:10 PM | markets.businessinsider.comMerck & Co., Inc. (NYSE:MRK) Trading 0.5% Higher - Still a Buy?Merck & Co., Inc. (NYSE:MRK) Trading 0.5% Higher - Here's What HappenedDecember 19 at 2:52 PM | marketbeat.comMerck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy TimeDecember 19 at 9:11 AM | seekingalpha.comDow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks NowDecember 19 at 8:46 AM | 247wallst.comMerck's HIV treatment meets main goal of two late-stage studiesDecember 19 at 6:59 AM | reuters.comMerck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 InfectionDecember 19 at 6:45 AM | businesswire.comMerck & Co., Inc. (NYSE:MRK) Trading Up 0.4% - Still a Buy?Merck & Co., Inc. (NYSE:MRK) Stock Price Up 0.4% - Here's What HappenedDecember 18, 2024 | marketbeat.comMerck pens $2bn deal for obesity drug from China's HansohDecember 18, 2024 | proactiveinvestors.comMerck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.December 18, 2024 | barrons.comMerck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing dealDecember 18, 2024 | cnbc.comMerck signs up to $2 bln obesity drug deal with Chinese biotech HansohDecember 18, 2024 | reuters.comMerck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor AgonistDecember 18, 2024 | businesswire.comSyntax Research Inc. Buys 10,000 Shares of Merck & Co., Inc. (NYSE:MRK)Syntax Research Inc. raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 459.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 12,175 shares of the company's stock after purchasing an additional 10,000 shares during the quarter. Syntax ResearcDecember 18, 2024 | marketbeat.comVirtu Financial LLC Reduces Stake in Merck & Co., Inc. (NYSE:MRK)Virtu Financial LLC reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 98.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,328 shares of the company's stock after selling 155,572 shares during theDecember 18, 2024 | marketbeat.comBernstein Keeps Their Hold Rating on Merck & Company (MRK)December 18, 2024 | markets.businessinsider.comMerck & Co. Inc. stock remains steady Tuesday, still outperforms marketDecember 17, 2024 | marketwatch.comMerck & Co., Inc. (NYSE:MRK) Trading Down 0.1% - Here's What HappenedMerck & Co., Inc. (NYSE:MRK) Trading Down 0.1% - Here's WhyDecember 17, 2024 | marketbeat.comMerck’s Oncology Strategy Shift: Hold Rating Amid Discontinued Immuno-Oncology ProgramsDecember 17, 2024 | markets.businessinsider.comMerck’s Biologics License Application for clesrovimab accepted by FDADecember 17, 2024 | markets.businessinsider.comIs Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?December 17, 2024 | insidermonkey.comMerck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV SeasonDecember 17, 2024 | businesswire.comMerck: Buy Opportunity Backed By GrowthDecember 17, 2024 | seekingalpha.comMerck & Co., Inc. (NYSE:MRK) Trading 0.5% Higher - Time to Buy?Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5% - Should You Buy?December 16, 2024 | marketbeat.comMerck discontinues development of 2 cancer drugs after trial failuresDecember 16, 2024 | reuters.comMerck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with PembrolizumabDecember 16, 2024 | businesswire.comChina Approves Merck's Keytruda To Treat Patients With Resectable Stage II, IIIA Or IIIB NSCLCDecember 16, 2024 | markets.businessinsider.comMerck's KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLCDecember 16, 2024 | businesswire.comMerck Has Become Very Cheap AgainDecember 16, 2024 | seekingalpha.comLord Abbett & CO. LLC Has $44.33 Million Stake in Merck & Co., Inc. (NYSE:MRK)Lord Abbett & CO. LLC lifted its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 127.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 390,353 shares of the company's stock after purchasing anDecember 15, 2024 | marketbeat.comB. Riley Wealth Advisors Inc. Has $14.41 Million Stake in Merck & Co., Inc. (NYSE:MRK)B. Riley Wealth Advisors Inc. lessened its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 13.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,497 shares of the compDecember 14, 2024 | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Up 0.3% - Still a Buy?Merck & Co., Inc. (NYSE:MRK) Shares Up 0.3% - Still a Buy?December 13, 2024 | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Position Reduced by Retirement Systems of AlabamaRetirement Systems of Alabama reduced its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,303,335 shares of the company's stock after selling 79,22December 13, 2024 | marketbeat.comOddo BHF Asset Management Sas Makes New Investment in Merck & Co., Inc. (NYSE:MRK)Oddo BHF Asset Management Sas bought a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 89,703 shares of the company's stock, valued at approximately $10,187,000. Several other largeDecember 13, 2024 | marketbeat.comBicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer PatientsDecember 13, 2024 | benzinga.comMerck: WELIREG Gets Positive EU CHMP Opinion For VHL Tumors, Advanced RCCDecember 13, 2024 | markets.businessinsider.comMerck & Co., Inc. (NYSE:MRK) Shares Purchased by Franklin Resources Inc.Franklin Resources Inc. raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 12.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,049,161 shares of the company's stock after acquirDecember 13, 2024 | marketbeat.comSynovus Financial Corp Raises Stock Holdings in Merck & Co., Inc. (NYSE:MRK)Synovus Financial Corp boosted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 8.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 324,981 shares of the company's stock after acquiring an additional 26,449 shares duringDecember 13, 2024 | marketbeat.comMerck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell CarcinomaDecember 13, 2024 | businesswire.comFY2026 EPS Forecast for Merck & Co., Inc. Reduced by AnalystDecember 13, 2024 | americanbankingnews.com Get Merck & Co., Inc. News Delivered to You Automatically Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] MRK Media Mentions By Week MRK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRK News Sentiment▼0.510.60▲Average Medical News Sentiment MRK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRK Articles This Week▼3924▲MRK Articles Average Week Get Merck & Co., Inc. News Delivered to You Automatically Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Eli Lilly and Company News Johnson & Johnson News AbbVie News Pfizer News Bristol-Myers Squibb News Zoetis News Royalty Pharma News Jazz Pharmaceuticals News Corcept Therapeutics News Perrigo News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:MRK) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thi...InvestorPlace | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck & Co., Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck & Co., Inc. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
